arrow
N

Nourhan El Ahmar

Brigham and Women's Hospital
H指数:6
被引数:137

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PASTA: versatile tyramide-oligonucleotide amplification for multimodal spatial biology

PASTA:适用于多模态空间生物学的通用酪胺寡核苷酸扩增

2026-08-170
PRE
Tertiary lymphoid structures harbour stem-like tumour-specific T cells

三级淋巴结构中存在干细胞样肿瘤特异性T细胞

Nature
IF48.5
2026-07-220
PRE
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma
2025-11-010
PRE
CD163+Tumor-Associated macrophages and clinical outcomes to First-Line nivolumab therapy in patients with metastatic clear cel renal cell carcinoma: insights from the HCRN GU16-260 trial

CD163+肿瘤相关巨噬细胞与转移性透明细胞肾细胞癌患者接受一线纳武利尤单抗治疗的临床结局:来自HCRN GU16-260试验的见解

2025-10-010
OAAI
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma

三级淋巴结构的存在和耗竭性组织驻留T细胞决定了肾细胞癌对PD-1阻断的临床反应

2025-10-010
OAAI
Tertiary Lymphoid Structures Predict Response to First-Line Nivolumab Therapy in Advanced Renal Cell Carcinoma: Findings from the HCRN GU16-260 Clinical Trial

三级淋巴结构预测晚期肾细胞癌一线Nivolumab治疗的反应: HCRN GU16-260临床试验的结果

2025-03-010
PRE
Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma

肉瘤样分化的表观基因组特征指导肾细胞癌的治疗

2024-06-010
OA
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
2023-12-074
OA
Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma

转移性透明细胞肾细胞癌对免疫检查点抑制异常反应的决定因素

2023-10-010
OAAI
Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC)

表观基因组分析提名主转录因子 (TFs) 驱动肾细胞癌 (RCC) 的肉瘤样分化

2023-08-150
PRE